Literature DB >> 11133613

Neither GABA(A) nor strychnine-sensitive glycine receptors are the sole mediators of MAC for isoflurane.

Y Zhang1, S Wu, E I Eger, J M Sonner.   

Abstract

UNLABELLED: Inhaled anesthetics produce immobility (a cardinal aspect of general anesthesia) by an action on the spinal cord, possibly by potentiating the responses of gamma-amino-n-butyric acid (GABA(A)) and glycine receptors to GABA and glycine. In this study, we antagonized GABA(A) and glycine responses by intrathecal administration of picrotoxin (a noncompetitive GABA(A) antagonist), strychnine (a competitive glycine antagonist), or combinations of these drugs. We measured the capacity of antagonist infusion to increase isoflurane MAC (the minimum alveolar concentration of anesthetic that prevents movement in response to noxious stimuli in 50% of subjects). We found that these potent GABA(A) and glycine receptor antagonists had a ceiling effect, either alone or in combination increasing the MAC of isoflurane by at most 47%. IMPLICATIONS: gamma-amino-n-butyric acid and glycine receptors may in part be responsible for the immobilizing action of isoflurane. They are not, however, the only receptors that contribute to isoflurane-induced immobility (i.e., that determine the MAC of isoflurane).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11133613     DOI: 10.1097/00000539-200101000-00024

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  13 in total

1.  GABA(A) receptor antagonism increases NMDA receptor inhibition by isoflurane at a minimum alveolar concentration.

Authors:  Robert J Brosnan
Journal:  Vet Anaesth Analg       Date:  2011-05       Impact factor: 1.648

Review 2.  Neurochemical modulators of sleep and anesthetic states.

Authors:  Christa J Van Dort; Helen A Baghdoyan; Ralph Lydic
Journal:  Int Anesthesiol Clin       Date:  2008

3.  Anesthetic effects on fictive locomotion in the rat isolated spinal cord.

Authors:  Steven L Jinks; Jason Andrada; Omar Satter
Journal:  Neuroreport       Date:  2011-09-14       Impact factor: 1.837

Review 4.  Molecular targets and mechanisms for ethanol action in glycine receptors.

Authors:  Daya I Perkins; James R Trudell; Daniel K Crawford; Ronald L Alkana; Daryl L Davies
Journal:  Pharmacol Ther       Date:  2010-04-23       Impact factor: 12.310

5.  Validation and insights of anesthetic action in an early vertebrate network: the isolated lamprey spinal cord.

Authors:  Steven L Jinks; Jason Andrada
Journal:  Anesth Analg       Date:  2011-07-25       Impact factor: 5.108

6.  Mutations M287L and Q266I in the glycine receptor α1 subunit change sensitivity to volatile anesthetics in oocytes and neurons, but not the minimal alveolar concentration in knockin mice.

Authors:  Cecilia M Borghese; Wei Xiong; S Irene Oh; Angel Ho; S John Mihic; Li Zhang; David M Lovinger; Gregg E Homanics; Edmond I Eger; R Adron Harris
Journal:  Anesthesiology       Date:  2012-10       Impact factor: 7.892

7.  Pre- and postsynaptic volatile anaesthetic actions on glycinergic transmission to spinal cord motor neurons.

Authors:  Gong Cheng; Joan J Kendig
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

8.  Nitrous oxide (N(2)O) requires the N-methyl-D-aspartate receptor for its action in Caenorhabditis elegans.

Authors:  P Nagele; L B Metz; C M Crowder
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-24       Impact factor: 11.205

Review 9.  Is a new paradigm needed to explain how inhaled anesthetics produce immobility?

Authors:  Edmond I Eger; Douglas E Raines; Steven L Shafer; Hugh C Hemmings; James M Sonner
Journal:  Anesth Analg       Date:  2008-09       Impact factor: 5.108

10.  Isoflurane depression of spinal nociceptive processing and minimum alveolar anesthetic concentration are not attenuated in mice expressing isoflurane resistant gamma-aminobutyric acid type-A receptors.

Authors:  JongBun Kim; Richard Atherley; David F Werner; Gregg E Homanics; Earl Carstens; Joseph F Antognini
Journal:  Neurosci Lett       Date:  2007-04-29       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.